[{"id":"e51bd763-cb21-4654-9b8f-68c7d6193455","acronym":"","url":"https://clinicaltrials.gov/study/NCT02648724","created_at":"2021-01-18T12:53:27.575Z","updated_at":"2024-07-02T16:36:08.469Z","phase":"Phase 1a","brief_title":"Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT02648724","lead_sponsor":"Symphogen A/S","biomarkers":" KRAS • MET","pipe":" | ","alterations":" MET amplification • KRAS wild-type • RAS wild-type","tags":["KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S95027"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2022-06-22"}]